Search results
Results from the WOW.Com Content Network
From 2019 to 2022, Anderson was CEO of Roche's pharmaceuticals division. [9] [10] During Anderson's tenure at Roche, he facilitated the company's transition from a focus on oncology. He headed the development and launch of new drugs to compensate for the decrease in revenues from oncology drugs whose patents had expired. [11]
move to sidebar hide. From Wikipedia, the free encyclopedia
Chairman and CEO of Paragon Biosciences, LLC Jeff Aronin (born December 8, 1967) is an American investor, entrepreneur, and biotechnology executive. He is founder, chairman and CEO of Paragon Biosciences, LLC, a global life science company that creates, builds, and funds innovative biology-based companies.
Endo Pharmaceuticals at various times was a significant funder of the American Pain Foundation, which has been accused of producing misleading and biased materials relating to opiod prescribing. [ 52 ] [ 53 ] APF shut down in 2012 after the United States Senate Committee on Finance began an investigation into the relationships between narcotic ...
This page was last edited on 23 December 2023, at 23:05 (UTC).; Text is available under the Creative Commons Attribution-ShareAlike 4.0 License; additional terms may apply.
The production facility on Parkdale Road in what was then Avon Township, Michigan (site now in Rochester, Michigan) was also a landmark in that vicinity and is now used by PAR Pharmaceuticals. In the 1950s, Parke-Davis employed Jonas Salk as a consultant on vaccine adjuvants. Parke-Davis was also involved in manufacturing the polio vaccine.
Pages in category "Health care companies based in Illinois" The following 25 pages are in this category, out of 25 total. This list may not reflect recent changes .
It was founded in 2000 by Jeffrey Aronin and is headquartered in Deerfield, Illinois. A major office is also located near Lebanon, New Jersey . Ovation is a privately held corporation based on a business model of acquiring mature but under-promoted pharmaceuticals, as well as pharmaceutical candidates which are far along the development and FDA ...